Analysts Set uniQure N.V. (NASDAQ:QURE) Price Target at $65.00

uniQure N.V. (NASDAQ:QURE) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $65.00.

A number of research analysts recently issued reports on QURE shares. The Goldman Sachs Group lifted their price target on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research note on Thursday, June 18th. Wells Fargo & Company increased their target price on uniQure from $60.00 to $75.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a report on Wednesday, June 17th. Finally, Barclays dropped their price objective on uniQure from $65.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, July 30th.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 21,167 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the sale, the director owned 25,996 shares in the company, valued at approximately $1,207,254.24. The trade was a 44.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the sale, the director owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This represents a 21.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 385,584 shares of company stock valued at $16,737,722 over the last three months. 4.65% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently bought and sold shares of QURE. Hennion & Walsh Asset Management Inc. increased its position in shares of uniQure by 107.3% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company’s stock worth $6,546,000 after purchasing an additional 73,566 shares in the last quarter. Royal Bank of Canada increased its stake in uniQure by 26.0% in the first quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company’s stock valued at $1,763,000 after purchasing an additional 22,248 shares during the period. Kalehua Capital Management LLC purchased a new stake in shares of uniQure in the first quarter valued at about $4,760,000. Voss Capital LP boosted its stake in shares of uniQure by 68.0% during the fourth quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company’s stock worth $5,025,000 after buying an additional 85,000 shares during the period. Finally, UBS Group AG boosted its stake in shares of uniQure by 139.7% during the fourth quarter. UBS Group AG now owns 491,454 shares of the biotechnology company’s stock worth $11,760,000 after buying an additional 286,465 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Price Performance

QURE stock opened at $44.50 on Tuesday. The business’s 50-day moving average is $44.30 and its two-hundred day moving average is $30.34. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The firm has a market capitalization of $3.09 billion, a P/E ratio of -11.10 and a beta of 0.94. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same period in the prior year, the firm posted ($0.69) earnings per share. Analysts anticipate that uniQure will post -3.82 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.